Ann: CE Mark Update, page-34

I doubt it, most regulatory bodies move pretty slowly. There's a chance we'll see it before Christmas, but if it's not by mid-December it likely won't be until mid-January.

As an aside, I was thinking OSL has similarities to CUV late 2014 - both had a fairly niche target market, and went for European approval as the first entry. CUV was trading in the $1.5 - $2 range before a run-up leading up to approval, when it spiked to around $4 (not sure how many shares they've issued since then, but it would have been somewhere south of $200M market cap post approval). There was a few years of sideways until strong revenue started coming in (late 2016) after which it has steadily risen to its current $1.5B+ MC

In terms of market size, EPP (disease for CUV's drug) has about 10,000 sufferers globally, and they charge about $120K per patient per annum. According to the last CEO presentation, there were 338k people diagnosed with pancreatic cancer in 2012, and another 782k with liver cancer. So that's about 100x more sufferers than EPP. Now I'm not sure what sort of pricing the OSL device would get, but even if it's 1/10th of what CUV charge, there's clearly a much bigger potential market for OSL than CUV (roughly 10X). $15B Market cap anyone? One can dream...